Key Takeaways
- Revenue guide cut on project deferral: Full-year FY27 revenue revised to ~₹600 crores from ₹650 crores because the 12,000 MT Dahej MCC expansion slipped to Q2 FY28, removing the expected H2 volume bump.
- H2 margin recovery promised: Management expects H2 EBITDA margins of at least 18%, up from ~15% in H1, driven by fixed overhead absorption, higher volumes, and a richer sales mix of co-processed and special grades.
- Safety-first utilization cap is lifting: MCC capacity utilization ran at 70-80%, not full, because post-Hyderabad-accident safety audits and equipment installs diverted focus from production; the last install completes mid-November, after which full 4,500 MT/quarter output is targeted.
- Preferential issue cancelled, CapEx funding open: The ₹200 crores promoter preferential allotment was called off after the stock price nearly doubled, and management has not yet decided the debt/equity mix for the ~₹200 crores Dahej CapEx.
- What to watch next quarter: Whether Q3 volumes actually hit the promised step-up after the mid-November safety-equipment completion, the pace of the co-processed mix shift, and any concrete funding plan for the Dahej expansion.
Revenue Walk & Guidance Revision
- The Dahej deferral: The full-year revenue guide was cut by ~₹50 crores because the new 12,000 MT MCC line at Dahej SEZ, originally expected to contribute in H2 FY27, is now commissioning only in Q2 FY28.
- H2 bridge to ~₹600 crores: H2 needs a ~40% revenue jump over H1, built on three legs: a capacity utilization ramp from mid-November at the existing plant, a catch-up in API dispatches deferred from Q2, and steady O&M segment growth.
- Realization tailwind: Average price realization rose to ₹262.83/kg in Q2 from ₹241.36 in Q1, and the H1 FY27 average of ₹252.16 compares favorably to H1 FY26's ₹216.42, reflecting the ongoing mix shift toward higher-value products.
- FY28 ambition: Management indicated next year "would be better" and "even more than" ₹800 crores, with the new 12,000 MT capacity alone contributing ~₹243 crores at 90% utilization and ~₹225/kg realization, plus growth in API and other segments.
Reddy: "earlier, in the beginning, we thought our new project MCC 12,000 metric tons capacity will come a little early, but some deferment would be there. Now, more or less, around INR 600 or so we can reach. In this, there would be a little slip."
Margin Trajectory & Mix Shift
- H1 margin snapshot: EBITDA margins ran at ~15% in H1, depressed by fixed overheads on sub-full utilization and the safety-related production distractions at the Hyderabad plant.
- H2 margin levers: Management expects margins to rise to at least 18% in H2, and "even better than 18%," because fixed overheads will not increase further while revenue rises, and the sales mix shifts decisively toward co-processed variants and special grades.
- Co-processed ramp: The existing co-processed mix is ~20% of sales; a 50% increase in that mix is expected in Q3 and Q4, directly lifting both top-line realization and margins.
- Sequential cadence: QoQ margin improvement has already been delivered (Q1 better than Q4, Q2 better than Q1), and management expects that pattern to continue through Q3 and Q4 as efficiency increases at all levels.
Reddy: "in the second half, there will not be further increase in fixed overhead costs. There will be increase in revenue, and the margins also will be on higher side. And sales mix also is going to change. The co-processed variants and then special grades will be on higher side in the next six months."
Capacity Utilization & the Safety Overhang
- Utilization constrained by safety, not demand: MCC capacity utilization was at 70-80% rather than the 90-95% the business is capable of, because after the Hyderabad plant accident management concentrated on internal, external, and customer safety audits and installed additional precautionary safety equipment on FBDs and dryers that no competitor in the segment has installed.
- Mid-November inflection: One remaining safety equipment installation will be completed by November 15th-20th; after that, the plant can go to full capacity utilization, with Q3 volumes stepping up from Q2's ~3,600-3,700 MT and Q4 reaching the full 4,500 MT per quarter.
- Demand is not the bottleneck: Orders are higher than production, and management sees no pressure from over-competitiveness; supply is the only constraint, and the company is known for quality, customer satisfaction, and timely supply.
Reddy: "After Hyderabad plant accident, we have concentrated more on safety audits, internal, external, and customer audits more on this. That's why when the concentration is on this, the production concentration was less. The main intention is the safety. Safety is the first priority."
API & O&M Segments
- API deferral, not shortfall: Q2 API revenue was lower because some customers requested dispatch be deferred to Q3; higher API revenues are expected in Q3 and Q4 as those orders convert.
- API full-year target: Nearly ₹100 crores is achievable for the full year, and up to ₹120 crores is possible if good orders materialize in Q4; the 100 kL capacity alone can deliver ₹100 crores, with value-added products pushing that to ₹120-150 crores.
- New API products: Trials have been completed for sparsentan and bempedoic acid, value-added products with higher margins that are proposed to be sold in Q3 and Q4.
- O&M steady: The O&M segment is steadily growing and now contributes almost 10-12% of revenue.
Dahej Expansion & CapEx Funding
- MCC and CCS timelines: The 12,000 MT-per-annum MCC expansion and the CCS facility at Dahej SEZ are both expected to be commissioned in Q2 FY28, with a one-year timeline from now to complete civil work; plant and machinery will be ordered in the last two to three months.
- Total CapEx required: Roughly ₹200 crores, split as around ₹100 crores for MCC and around ₹90 crores for CCS; most equipment will be sourced domestically.
- Funding plan unresolved: The ₹200 crores preferential allotment to promoters at ₹26.4/share was called off after the share price rose sharply to almost ₹39 and the company received calls from well-wishers and prospective investors saying dilution at that price was unwise.
- Debt/equity mix open: Management said both debt and equity options are open, some portion may be debt and some equity, and an announcement will come at the appropriate time; a preferential issue is not ruled out but not wise to discuss now. When asked what peak debt level or net debt-to-EBITDA ratio the company would be comfortable with, management responded they have not yet decided and have not thought about it as of now.
Reddy: "After the issuance was decided... we received many calls from well-wishers and prospective investors, and they said that, 'Why you are diluting so much at this price?' ... it sharply went up to almost INR 39, and we received many calls. We missed the opportunity, and then at this point of time, it's not wise to dilute at this rate."
Insurance Claim & Other Updates
- Claim timeline: All queries from the insurer have been answered, surveyor and insurance company discussions are ongoing, and scrap has been auctioned by the insurance people; receipt of the claim is expected by November or December, before December, with a ~5-10% discount on the ~₹49 crores indicated.
- Product launches: Four new PureCoat coating offerings were launched: PureCoat Flavor (odor masking), PureCoat TiO2 Free, PureCoat Pearl (natural silicate/silica-based pigments with iron oxide), and PureCoat NP (natural polymer pullulan as an alternative to synthetic polymers).
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year FY27 revenue | ~₹600 crores (revised from ₹650 crores) | FY27 |
| H2 EBITDA margin | At least 18%, "even better than 18%" | H2 FY27 |
| Capacity utilization ramp | Full 4,500 MT/quarter after last safety equipment install | From mid-November; Q4 FY27 |
| Co-processed/special grades mix | 50% increase over existing ~20% mix | Q3 and Q4 FY27 |
| API full-year revenue | Nearly ₹100 crores, up to ₹120 crores possible | FY27 |
| Insurance claim receipt | ~₹49 crores less 5-10% discount | November or December, before December |
| Dahej MCC12,000 MT commissioning | Commercial production start | Q2 FY28 |
| Dahej CCS facility commissioning | Commercial production start | Q2 FY28 |
| Total Dahej CapEx | ~₹200 crores (₹100 crores MCC, ₹90 crores CCS) | One year from now |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Total operating income | ₹130.45 cr |
| EBITDA | ₹19.2 cr |
| EBITDA margin | 14.72% |
| Net profit | ₹8.78 cr |
| Net profit margin | 6.82% |
| MCC segment revenue | ₹91.22 cr, 70% of total revenue |
| API segment revenue | ₹16.67 cr, 13% of total revenue |
| O&M segment revenue | ₹13.93 cr, 11% of total revenue |
| Full-year FY27 revenue guidance | ~₹600 cr, revised from ₹650 cr earlier |
| Full-year FY27 EBITDA margin guidance | ~18%, H2 expected at least 18% or better |
| MCC volume produced and sold (H1 FY27) | 7,128 metric tons, Q2 volume ~3,700 metric tons |
| Overall capacity utilization (H1 FY27) | ~80%, Dahej ~79.91%, Jhagadia ~79% |
| Average price realization | ₹262.83, up from ₹241.36 in Q1 FY27 and ₹216.42 in H1 FY26 |
| Co-processed and special grades mix | ~20% of sales mix, expected 50% increase in Q3 and Q4 |
| API capacity | 100 kL, can deliver up to ₹100 cr, up to ₹150 cr with value-added products |
| Insurance claim receivable | ~₹49 cr, with ~10% discount indicated by insurer, expected by Nov-Dec |
| CapEx spent to date (MCC and CCS combined) | ~₹29-30 cr |
| Total CapEx required (MCC and CCS) | ~₹200 cr, ₹100 cr for MCC and ₹90 cr for CCS |